Intellia Therapeutics (NTLA) Could Be 50% Undervalued After Its Q2 2026 Earnings
Intellia Therapeutics (NTLA) reported Q2 2026 results that kept the company in loss making territory, although the net loss and loss per share for both the quarter and first half improved versus last year.
See our latest analysis for Intellia Therapeutics.
Intellia Therapeutics’ latest earnings release on 6 August came after a period where the stock’s year to date share price return of 30.51% is set against a 1 year total shareholder return of 11.92% and a 3 year total shareholder return that is down 69.12%, which points to improving short term momentum but a mixed longer term record.
If the Q2 update has you rethinking exposure to high growth healthcare and biotech, this can be a useful moment to scan the wider field and see which healthcare AI stocks stand out through the 43 healthcare AI stocks
After a sharp year to date rebound in Intellia Therapeutics, but a much weaker multi year record, the stock now sits at an interesting crossroads. Do the current valuation markers still leave enough upside to justify the risk?
Most Popular Narrative: 49.8% Undervalued
At a last close of $12.02 versus a narrative fair value of about $23.94, Intellia Therapeutics is framed as significantly undervalued, with that gap heavily tied to expectations around its gene editing pipeline and future approvals.
Rapid technological and regulatory advancements in gene-editing, including increased healthcare investments, accelerating review pathways, and support for first-in-class CRISPR therapies, create a favorable environment for Intellia's platform to secure approvals, forge additional partnership/licensing opportunities, and achieve sustainable, recurring non-dilutive revenues through both commercialization and collaborations, increasing top-line growth and earnings potential.
Want to see what sits behind that confidence in Intellia Therapeutics? The narrative leans on aggressive revenue expansion, much stronger margins, and a premium future earnings multiple. Curious which specific assumptions pull that $23.94 fair value so far above today’s price.
Result: Fair Value of $23.94 (UNDERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, Intellia Therapeutics still faces meaningful risks, including heavy R&D spending with ongoing losses and dependence on late stage trial outcomes that could shift sentiment quickly.
Find out about the key risks to this Intellia Therapeutics narrative.
Another View On Intellia Therapeutics’ Valuation
The analyst narrative sees Intellia Therapeutics as materially undervalued at $12.02 compared with a $23.94 fair value estimate. Yet on a P/S basis the stock trades at about 28.3x, far above the US Biotechs industry at 11.5x, peers at 10.6x, and a fair ratio of 0.1x, which suggests a lot has to go right for today’s price to hold.
That gap on sales multiples can signal rich expectations and higher downside risk if sentiment turns, even when longer term models flag upside. This raises a key question: which lens should investors rely on when the story is this dependent on future execution?
See what the numbers say about this price — find out in our valuation breakdown.
Next Steps
With sentiment on Intellia Therapeutics split between promise and pressure, it makes sense to move quickly and stress test the full picture for yourself. Start by weighing both sides of the story through the 2 key rewards and 3 important warning signs
Looking for more investment ideas beyond Intellia Therapeutics?
If Intellia Therapeutics has sharpened your focus, do not stop here. Use this moment to broaden your watchlist and pressure test fresh ideas across sectors.
- Target potential mispricings by scanning the 51 high quality undervalued stocks that combine solid fundamentals with more attractive entry points.
- Strengthen portfolio resilience by zeroing in on companies highlighted in the 83 resilient stocks with low risk scores that score well on financial stability and downside protection.
- Get ahead of the crowd by reviewing the screener containing 21 high quality undiscovered gems that the market may not be fully paying attention to yet.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com